These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 9473235

  • 1. The AML1/ETO(MTG8) and AML1/Evi-1 leukemia-associated chimeric oncoproteins accumulate PEBP2beta(CBFbeta) in the nucleus more efficiently than wild-type AML1.
    Tanaka K, Tanaka T, Kurokawa M, Imai Y, Ogawa S, Mitani K, Yazaki Y, Hirai H.
    Blood; 1998 Mar 01; 91(5):1688-99. PubMed ID: 9473235
    [Abstract] [Full Text] [Related]

  • 2. Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression of co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigenic properties.
    Zent C, Kim N, Hiebert S, Zhang DE, Tenen DG, Rowley JD, Nucifora G.
    Curr Top Microbiol Immunol; 1996 Mar 01; 211():243-52. PubMed ID: 8585955
    [Abstract] [Full Text] [Related]

  • 3. Dual functions of the AML1/Evi-1 chimeric protein in the mechanism of leukemogenesis in t(3;21) leukemias.
    Tanaka T, Mitani K, Kurokawa M, Ogawa S, Tanaka K, Nishida J, Yazaki Y, Shibata Y, Hirai H.
    Mol Cell Biol; 1995 May 01; 15(5):2383-92. PubMed ID: 7739522
    [Abstract] [Full Text] [Related]

  • 4. The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells.
    Kurokawa M, Mitani K, Imai Y, Ogawa S, Yazaki Y, Hirai H.
    Blood; 1998 Dec 01; 92(11):4003-12. PubMed ID: 9834202
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Leukemogenesis by CBF oncoproteins.
    Friedman AD.
    Leukemia; 1999 Dec 01; 13(12):1932-42. PubMed ID: 10602413
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia.
    Mitani K, Ogawa S, Tanaka T, Miyoshi H, Kurokawa M, Mano H, Yazaki Y, Ohki M, Hirai H.
    EMBO J; 1994 Feb 01; 13(3):504-10. PubMed ID: 8313895
    [Abstract] [Full Text] [Related]

  • 10. Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction.
    Kozu T, Miyoshi H, Shimizu K, Maseki N, Kaneko Y, Asou H, Kamada N, Ohki M.
    Blood; 1993 Aug 15; 82(4):1270-6. PubMed ID: 8353289
    [Abstract] [Full Text] [Related]

  • 11. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript.
    Miyoshi H, Kozu T, Shimizu K, Enomoto K, Maseki N, Kaneko Y, Kamada N, Ohki M.
    EMBO J; 1993 Jul 15; 12(7):2715-21. PubMed ID: 8334990
    [Abstract] [Full Text] [Related]

  • 12. The chimeric genes AML1/MDS1 and AML1/EAP inhibit AML1B activation at the CSF1R promoter, but only AML1/MDS1 has tumor-promoter properties.
    Zent CS, Mathieu C, Claxton DF, Zhang DE, Tenen DG, Rowley JD, Nucifora G.
    Proc Natl Acad Sci U S A; 1996 Feb 06; 93(3):1044-8. PubMed ID: 8577711
    [Abstract] [Full Text] [Related]

  • 13. The AML1/ETO fusion protein activates transcription of BCL-2.
    Klampfer L, Zhang J, Zelenetz AO, Uchida H, Nimer SD.
    Proc Natl Acad Sci U S A; 1996 Nov 26; 93(24):14059-64. PubMed ID: 8943060
    [Abstract] [Full Text] [Related]

  • 14. ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: implications for t(8;21) leukemogenesis and monitoring residual disease.
    Erickson PF, Dessev G, Lasher RS, Philips G, Robinson M, Drabkin HA.
    Blood; 1996 Sep 01; 88(5):1813-23. PubMed ID: 8781439
    [Abstract] [Full Text] [Related]

  • 15. The AML1/Evi-1 fusion protein in the t(3;21) translocation exhibits transforming activity on Rat1 fibroblasts with dependence on the Evi-1 sequence.
    Kurokawa M, Ogawa S, Tanaka T, Mitani K, Yazaki Y, Witte ON, Hirai H.
    Oncogene; 1995 Sep 07; 11(5):833-40. PubMed ID: 7675444
    [Abstract] [Full Text] [Related]

  • 16. In vitro catalytic activities of DNA/RNA chimeric hammerhead ribozymes against AML1-MTG8 mRNA, a fused gene transcript in acute myeloid leukemia with t(8;21).
    Kozu T, Sueoka E, Okabe S, Sueoka N, Komori A, Fujiki H.
    Biochimie; 1996 Sep 07; 78(11-12):1067-73. PubMed ID: 9150886
    [Abstract] [Full Text] [Related]

  • 17. Molecular mechanisms of leukemogenesis by AML1/EVI-1.
    Mitani K.
    Oncogene; 2004 May 24; 23(24):4263-9. PubMed ID: 15156182
    [Abstract] [Full Text] [Related]

  • 18. A conserved cysteine residue in the runt homology domain of AML1 is required for the DNA binding ability and the transforming activity on fibroblasts.
    Kurokawa M, Tanaka T, Tanaka K, Hirano N, Ogawa S, Mitani K, Yazaki Y, Hirai H.
    J Biol Chem; 1996 Jul 12; 271(28):16870-6. PubMed ID: 8663420
    [Abstract] [Full Text] [Related]

  • 19. Specific protein redirection as a transcriptional therapy approach for t(8;21) leukemia.
    Steffen B, Serve H, Berdel WE, Agrawal S, Linggi B, Büchner T, Hiebert SW, Müller-Tidow C.
    Proc Natl Acad Sci U S A; 2003 Jul 08; 100(14):8448-53. PubMed ID: 12819347
    [Abstract] [Full Text] [Related]

  • 20. The partner gene of AML1 in t(16;21) myeloid malignancies is a novel member of the MTG8(ETO) family.
    Gamou T, Kitamura E, Hosoda F, Shimizu K, Shinohara K, Hayashi Y, Nagase T, Yokoyama Y, Ohki M.
    Blood; 1998 Jun 01; 91(11):4028-37. PubMed ID: 9596646
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.